Therapeutic nuclease compositions and methods
AssigneeUniversity of Washington
InventorsJeffrey A. Ledbetter, Martha Hayden-Ledbetter, Keith Elkon, Xizhang Sun
Life of this patent
Estimating the term…
Abstract
Hybrid nuclease molecules and methods for treating an immune-related disease or disorder in a mammal, and a pharmaceutical composition for treating an immune-related disease in a mammal.
Claims30
A method for reducing or inhibiting interferon (IFN) production in a subject comprising administering to the subject a composition comprising:
- a polypeptide consisting of human RNase 1 operatively coupled with or without a linker to a mutant human IgG1 Fc domain, wherein the Fc domain comprises a P238S mutation and a P331S mutation, numbering according to the EU index, and wherein the Fc domain does not contain a variable region that binds antigen;
- and a pharmaceutically acceptable carrier.
A method of inhibiting production of interferon in a subject, comprising administering to the subject a composition comprising a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:
- 96;
- and a pharmaceutically acceptable carrier.
A method of reducing production of interferon in a subject, comprising administering to the subject a composition comprising a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:
- 96;
- and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.